

Mafalda Ramos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6449755/publications.pdf>

Version: 2024-02-01

13
papers

136
citations

1478505

6
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

194
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. Value in Health, 2020, 23, 1163-1170.	0.3	32
2	Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease. Diabetes Therapy, 2019, 10, 2153-2167.	2.5	20
3	Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach. Value in Health Regional Issues, 2019, 18, 36-46.	1.2	14
4	<p>Cost versus utility of acclidinium bromide 400 μg plus formoterol fumarate dihydrate 12 μg compared to acclidinium bromide 400 μg alone in the management of moderate-to-severe COPD</p>. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 445-456.	1.9	13
5	Cost-effectiveness of physical activity in the management of COPD patients in the UK. International Journal of COPD, 2019, Volume 14, 227-239.	2.3	12
6	Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes. Journal of Comparative Effectiveness Research, 2020, 9, 781-794.	1.4	11
7	The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark. Journal of Comparative Effectiveness Research, 2022, 11, 29-37.	1.4	8
8	Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost Effectiveness and Resource Allocation, 2021, 19, 46.	1.5	7
9	Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Portugal. Revista Portuguesa De Cardiologia, 2021, 40, 109-115.	0.5	6
10	Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China. Journal of Comparative Effectiveness Research, 2021, 10, 469-480.	1.4	5
11	Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. Medical Decision Making, 2022, 42, 599-611.	2.4	5
12	1292-P: Projected Long-Term Clinical Benefit and Cost-Effectiveness of Empagliflozin Compared with Glimepiride in Patients with Type 2 Diabetes in China. Diabetes, 2019, 68, 1292-P.	0.6	2
13	Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico. Value in Health Regional Issues, 2018, 17, 164-173.	1.2	1